T2G 2018 Q3 Performance Summary

| Organization <br> Code | Track | Prevalence of <br> Type 2 Diabetes | HbA1c <br> Control | BP Control | Medical <br> Attention for <br> Nephropathy | Lipid <br> Management | Diabetes Care <br> Bundle |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| BC6 | Core | $22.7 \%$ | $72.4 \%$ | $68.9 \%$ | $95.2 \%$ | $84.5 \%$ | $39.3 \%$ |
| BH5 | Core | $8.5 \%$ | $66.8 \%$ | $89.7 \%$ | $92.3 \%$ | $63.1 \%$ | $42.7 \%$ |
| BT5 | Core | $13.7 \%$ | $72.0 \%$ | $65.4 \%$ | $87.0 \%$ | $73.5 \%$ | $33.3 \%$ |
| BU9 | Core | $15.1 \%$ | $69.5 \%$ | $80.4 \%$ | $82.7 \%$ | $88.2 \%$ | $44.4 \%$ |
| CJ7 | Core | $27.9 \%$ | $69.9 \%$ | $69.5 \%$ | $87.9 \%$ | $67.9 \%$ | $31.4 \%$ |
| CJ8 | Core | $11.3 \%$ | $62.2 \%$ | $70.8 \%$ | $88.9 \%$ | $73.2 \%$ | $31.6 \%$ |
| CM4 | Core | $15.2 \%$ | $64.6 \%$ | $69.5 \%$ | $86.1 \%$ | $69.6 \%$ | $31.4 \%$ |
| CR1 | Core | $9.0 \%$ | $77.5 \%$ | $81.3 \%$ | $89.0 \%$ | $69.3 \%$ | $32.5 \%$ |
| DQ2 | Core | $17.2 \%$ | $62.6 \%$ | $78.6 \%$ | $94.0 \%$ | $83.1 \%$ | $41.7 \%$ |
| DR7 | Core | $17.6 \%$ | $73.2 \%$ | $84.9 \%$ | $94.0 \%$ | $99.0 \%$ | $61.3 \%$ |
| DV4 | Core | $24.1 \%$ | $71.6 \%$ | $78.2 \%$ | $86.5 \%$ | $68.6 \%$ | $37.8 \%$ |
| ED9 | Core | $13.2 \%$ | $79.9 \%$ | $91.5 \%$ | $96.2 \%$ | $74.1 \%$ | $55.1 \%$ |
| EH2 | Core | $15.1 \%$ | $75.4 \%$ | $60.7 \%$ | $89.4 \%$ | $53.0 \%$ | $28.9 \%$ |
| EK2 | Core | $15.6 \%$ | $58.5 \%$ | $65.2 \%$ | $62.5 \%$ | $62.7 \%$ | $17.8 \%$ |
| EM3 | Core | $12.7 \%$ | $71.9 \%$ | $82.0 \%$ | $89.3 \%$ | $76.5 \%$ | $44.4 \%$ |
| EM4 | Core | $9.8 \%$ | $58.4 \%$ | $75.0 \%$ | $92.4 \%$ | $53.3 \%$ | $27.6 \%$ |
| EN9 | Core | $13.3 \%$ | $65.6 \%$ | $74.9 \%$ | $90.8 \%$ | $76.9 \%$ | $37.2 \%$ |
| ER3 | Core | $13.9 \%$ | $67.6 \%$ | $76.3 \%$ | $86.5 \%$ | $70.4 \%$ | $36.0 \%$ |
| EU5 | Core | $7.1 \%$ | $75.1 \%$ | $84.5 \%$ | $82.7 \%$ | $78.7 \%$ | $45.7 \%$ |
| FV6 | Core | $12.5 \%$ | $64.1 \%$ | $75.0 \%$ | $79.7 \%$ | $61.3 \%$ | $29.4 \%$ |
| GB7 | Basic | $10.9 \%$ | $68.9 \%$ |  |  |  |  |
| GE4 | Core | $16.8 \%$ | $64.9 \%$ | $76.6 \%$ | $87.7 \%$ | $70.4 \%$ | $35.9 \%$ |
| GT1 | Core | $19.1 \%$ | $66.1 \%$ | $76.3 \%$ | $91.7 \%$ | $78.7 \%$ | 40 |
| GT3 | Core | $16.1 \%$ | $68.0 \%$ | $74.2 \%$ | $90.7 \%$ | $72.4 \%$ | $38.9 \%$ |
| JB1 | Core | $13.8 \%$ | $69.7 \%$ | $71.1 \%$ | $88.2 \%$ | $70.4 \%$ | $33.9 \%$ |
| JG2 | Basic | $7.4 \%$ | $75.6 \%$ |  |  |  |  |
| JH8 | Core | $23.5 \%$ | $67.1 \%$ | $80.2 \%$ | $92.6 \%$ | $78.8 \%$ | $41.1 \%$ |
| JL8 | Core | $13.7 \%$ | $69.8 \%$ | $64.7 \%$ | $95 \%$ | $63.0 \%$ | $33.5 \%$ |
| JM2 | Core | $13.2 \%$ | $75.9 \%$ | $87.5 \%$ | $82.4 \%$ | $72.0 \%$ | $44.0 \%$ |
| JM6 | Core | $17.4 \%$ | $70.2 \%$ | $72.1 \%$ | $88.8 \%$ | $72.3 \%$ | $35.1 \%$ |

T2G 2018 Q3 Performance Summary

| Organization Code | Track | Prevalence of Type 2 Diabetes | HbA1c <br> Control | BP Control | Medical Attention for Nephropathy | Lipid <br> Management | Diabetes Care Bundle |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| JN9 | Core | 21.9\% | 67.5\% | 74.3\% | 89.1\% | 81.7\% | 40.8\% |
| KN3 | Core | 13.4\% | 73.0\% | 73.6\% | 89.8\% | 73.1\% | 39.2\% |
| KU8 | Core | 14.5\% | 77.4\% | 86.1\% | 95.2\% | 81.2\% | 54.0\% |
| LK5 | Core | 24.2\% | 71.7\% | 89.6\% | 93.0\% | 71.9\% | 47.9\% |
| LV6 | Core | 16.2\% | 69.4\% | 75.2\% | 88.7\% | 79.0\% | 36.9\% |
| LY2 | Core | 16.0\% | 71.3\% | 83.9\% | 74.3\% | 63.2\% | 30.3\% |
| MC2 | Core | 17.7\% | 66.8\% | 67.1\% | 94.3\% | 88.7\% | 41.8\% |
| NC9 | Core | 22.1\% | 70.1\% | 69.9\% | 90.7\% | 78.4\% | 39.0\% |
| NS5 | Core | 19.3\% | 76.1\% | 80.7\% | 82.3\% | 73.3\% | 42.6\% |
| PB9 | Core | 14.4\% | 64.2\% | 82.4\% | 89.8\% | 54.7\% | 29.1\% |
| PE8 | Core | 14.8\% | 68.6\% | 80.0\% | 87.6\% | 71.1\% | 38.5\% |
| PQ6 | Core | 13.8\% | 75.3\% | 92.5\% | 92.1\% | 82.5\% | 57.6\% |
| PT8 | Core | 12.1\% | 66.9\% | 85.4\% | 86.9\% | 70.6\% | 42.2\% |
| QB1 | Core | 24.0\% | 69.8\% | 74.2\% | 93.4\% | 83.2\% | 43.1\% |
| QC4 | Core | 19.8\% | 72.3\% | 77.8\% | 91.8\% | 77.7\% | 45.3\% |
| QF1 | Core | 14.1\% | 66.6\% | 74.0\% | 81.7\% | 65.7\% | 34.8\% |
| QH1 | Core | 13.0\% | 68.8\% | 75.9\% | 87.6\% | 74.5\% | 38.1\% |
| QJ2 | Core | 11.6\% | 74.2\% | 78.8\% | 88.9\% | 80.9\% | 45.9\% |
| QP8 | Core | 10.6\% | 79.1\% | 93.4\% | 91.0\% | 71.5\% | 53.0\% |
| QR4 | Core | 14.8\% | 65.6\% | 67.7\% | 85.7\% | 70.0\% | 40.0\% |
| SE2 | Core | 13.6\% | 68.1\% | 78.8\% | 82.2\% | 79.9\% | 39.1\% |
| TE7 | Core | 14.3\% | 70.8\% | 74.2\% | 93.8\% | 68.7\% | 38.0\% |
| TZ5 | Core | 14.3\% | 68.8\% | 75.8\% | 88.6\% | 78.9\% | 34.5\% |
| TZ9 | Core | 10.2\% | 58.2\% | 74.6\% | 83.1\% | 74.3\% | 32.1\% |
| UE5 | Core | 19.9\% | 66.9\% | 73.8\% | 87.5\% | 80.5\% | 38.4\% |
| UG9 | Core | 12.8\% | 74.8\% | 82.6\% | 91.0\% | 83.4\% | 51.0\% |
| UH4 | Core | 17.8\% | 67.7\% | 71.8\% | 79.9\% | 62.8\% | 32.8\% |
| UP3 | Core | 14.3\% | 67.0\% | 78.4\% | 88.9\% | 71.9\% | 38.2\% |
| UQ1 | Basic | 22.0\% | 67.9\% |  |  |  |  |
| UQ5 | Core | 14.8\% | 66.3\% | 67.3\% | 88.2\% | 70.6\% | 31.5\% |

T2G 2018 Q3 Performance Summary

| Organization <br> Code | Track | Prevalence of <br> Type 2 Diabetes | HbA1c <br> Control | BP Control | Medical <br> Atention for | Lipid | Diabetes Care <br> Bundle |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| UY6 | Core | $12.2 \%$ | $68.5 \%$ | $82.1 \%$ | $92.8 \%$ | $77.9 \%$ | $59.6 \%$ |
| UY8 | Core | $14.4 \%$ | $73.5 \%$ | $77.6 \%$ | $92.1 \%$ | $77.4 \%$ | $45.4 \%$ |
| VD1 | Core | $6.7 \%$ | $80.8 \%$ | $87.5 \%$ | $98.8 \%$ | $70.0 \%$ | $51.7 \%$ |
| VD3 | Basic | $13.0 \%$ | $58.0 \%$ |  |  |  |  |
| VG1 | Core | $20.2 \%$ | $56.3 \%$ | $77.2 \%$ | $90.7 \%$ | $81.5 \%$ | $36.9 \%$ |
| VK4 | Basic | $19.9 \%$ | $70.5 \%$ |  |  |  |  |
| VP7 | Core | $11.4 \%$ | $67.2 \%$ | $72.5 \%$ | $71.6 \%$ | $66.9 \%$ | $28.7 \%$ |
| VR4 | Core | $13.4 \%$ | $80.0 \%$ | $84.2 \%$ | $99.6 \%$ | $94.6 \%$ | $68.2 \%$ |
| VX4 | Core | $3.9 \%$ | $81.5 \%$ | $81.8 \%$ | $88.8 \%$ | $77.0 \%$ | $47.4 \%$ |
| WP3 | Core | $8.8 \%$ | $59.8 \%$ | $75.8 \%$ | $84.8 \%$ | $70.9 \%$ | $33.7 \%$ |
| WR4 | Core | $16.8 \%$ | $68.5 \%$ | $75.9 \%$ | $91.1 \%$ | $81.8 \%$ | $42.3 \%$ |
| WU8 | Core | $15.4 \%$ | $72.0 \%$ | $74.1 \%$ | $86.8 \%$ | $75.7 \%$ | $40.2 \%$ |
| WX4 | Core | $9.5 \%$ | $69.8 \%$ | $72.0 \%$ | $86.4 \%$ | $65.8 \%$ | $33.5 \%$ |
| WX9 | Core | $5.2 \%$ | $74.7 \%$ | $76.5 \%$ | $87.5 \%$ | $68.5 \%$ | $38.9 \%$ |
| XB5 | Core | $12.9 \%$ | $72.1 \%$ | $79.8 \%$ | $90.3 \%$ | $80.2 \%$ | $47.4 \%$ |
| XH9 | Core | $7.2 \%$ | $75.0 \%$ | $77.7 \%$ | $90.3 \%$ | $69.5 \%$ | $41.4 \%$ |
| XK8 | Core | $8.0 \%$ | $76.4 \%$ | $81.7 \%$ | $89.3 \%$ | $84.1 \%$ | $51.3 \%$ |
| XL7 | Core | $18.5 \%$ | $74.2 \%$ | $81.0 \%$ | $85.8 \%$ | $77.9 \%$ | $44.6 \%$ |
| XX3 | Core | $10.8 \%$ | $67.9 \%$ | $78.8 \%$ | $84.2 \%$ | $66.7 \%$ | $35.6 \%$ |
| XZ1 | Core | $18.2 \%$ | $68.0 \%$ | $71.9 \%$ | $87.1 \%$ | $69.9 \%$ | $35.7 \%$ |
| YM4 | Core | $9.3 \%$ | $68.9 \%$ | $74.7 \%$ | $93.7 \%$ | $85.8 \%$ | $45.4 \%$ |
| YP8 | Core | $12.8 \%$ | $67.0 \%$ | $75.4 \%$ | $87.1 \%$ | $65.9 \%$ | $34.7 \%$ |
| YX5 | Core | $19.2 \%$ | $69.1 \%$ | $80.6 \%$ | $91.0 \%$ | $76.1 \%$ | $44.0 \%$ |
| YZ3 | Core | $19.1 \%$ | $68.0 \%$ | $73.0 \%$ | $83.8 \%$ | $64.6 \%$ | $34.5 \%$ |
| ZD8 | Core | $11.6 \%$ | $61.6 \%$ | $75.5 \%$ | $83.0 \%$ | $67.7 \%$ | $35.1 \%$ |
| ZF1 | Basic | $14.1 \%$ | $55.6 \%$ |  |  |  |  |
| ZT9 | Core | $15.9 \%$ | $71.5 \%$ | $84.9 \%$ | $93.8 \%$ | $79.0 \%$ | 48 |
| Group Weighted Averages: | $14.7 \%$ | $69.5 \%$ | $77.3 \%$ | $88.1 \%$ |  |  |  |
|  |  |  |  |  |  | $73.8 \%$ | $40.2 \%$ |

